88 related articles for article (PubMed ID: 2138167)
41. Immunohistochemical detection of the ras oncogene product p21 in advanced ovarian cancer. Lack of correlation with clinical outcome.
Rodenburg CJ; Koelma IA; Nap M; Fleuren GJ
Arch Pathol Lab Med; 1988 Feb; 112(2):151-4. PubMed ID: 3276289
[TBL] [Abstract][Full Text] [Related]
42. [Overexpression of c-erbB-2 oncogene in primary ovarian cancers: incidence and prognostic significance in 243 patients].
Meden H; Marx D; Rath W; Kuhn W; Hinney B; Schauer A
Geburtshilfe Frauenheilkd; 1992 Nov; 52(11):667-73. PubMed ID: 1360438
[TBL] [Abstract][Full Text] [Related]
43. Prognostic importance of the nucleolar organizer region score in ovarian epithelial tumors.
Zergeroğlu S; Aksakal O; Demirtürk F; Gökmen O
Gynecol Obstet Invest; 2001; 51(1):60-3. PubMed ID: 11150878
[TBL] [Abstract][Full Text] [Related]
44. Molecular Genetic Analysis of Ovarian Brenner Tumors and Associated Mucinous Epithelial Neoplasms: High Variant Concordance and Identification of Mutually Exclusive RAS Driver Mutations and MYC Amplification.
Tafe LJ; Muller KE; Ananda G; Mitchell T; Spotlow V; Patterson SE; Tsongalis GJ; Mockus SM
Am J Pathol; 2016 Mar; 186(3):671-7. PubMed ID: 26797085
[TBL] [Abstract][Full Text] [Related]
45. Ovarian cystadenoma as a characteristic feature of families with hereditary ovarian cancers unassociated with BRCA1 and BRCA2 mutations.
Menkiszak J; Brzosko M; Górski B; Fliciński J; Jakubowska A; Zebiełowicz D; Gronwald J; Huzarski T; Byrski T; Teresiński L; Chosia M; Rzepka-Górska I; Lubiński J
J Appl Genet; 2004; 45(2):255-63. PubMed ID: 15131356
[TBL] [Abstract][Full Text] [Related]
46. Carcinoembryonic antigen in human ovarian neoplasms.
Marchand A; Fenoglio CM; Pascal R; Richart RM; Bennett S
Cancer Res; 1975 Dec; 35(12):3807-10. PubMed ID: 1192434
[TBL] [Abstract][Full Text] [Related]
47. [Study of the amplification and expression of c-erbB2 oncogene in epithelial ovarian tumors].
Hou Y; Wang M; Liu W
Zhonghua Zhong Liu Za Zhi; 1996 Nov; 18(6):426-8. PubMed ID: 9387293
[TBL] [Abstract][Full Text] [Related]
48. Management of massive ovarian tumors.
Pretorius RG; Matory WE; LaFontaine D
Surg Gynecol Obstet; 1989 Dec; 169(6):532-6. PubMed ID: 2554517
[TBL] [Abstract][Full Text] [Related]
49. Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors.
Huang LW; Garrett AP; Bell DA; Welch WR; Berkowitz RS; Mok SC
Gynecol Oncol; 2000 Jun; 77(3):369-76. PubMed ID: 10831344
[TBL] [Abstract][Full Text] [Related]
50. Lamin C protein deficiency in the primary fibroblasts from a new laminopathy case with ovarian cystadenoma.
Cai MY; Liang H; Li M; Bi Y; Chen X; Sun WP; Weng JP
Chin Med J (Engl); 2010 Aug; 123(16):2237-43. PubMed ID: 20819672
[TBL] [Abstract][Full Text] [Related]
51. [Clinical and morphological developmental peculiarities in ovarian myxoadenocarcinoma].
Lenczewski A; Musiatowicz B; Drozdzewicz M; Lotocki W
Wiad Lek; 1982 Jul; 35(9):595-8. PubMed ID: 7123951
[No Abstract] [Full Text] [Related]
52. [Prognostic significance of cellular DNA content and AgNOR count in ovarian cystadenoma].
Lu XL; Yi WM; Wang LF
Ai Zheng; 2003 Jan; 22(1):62-5. PubMed ID: 12561439
[TBL] [Abstract][Full Text] [Related]
53. [Chromosome anomalies in 2 cases of human ovarian cancer].
de Blois MC; Boyer P; Bénard J; Riou G
C R Acad Sci III; 1986; 302(3):81-6. PubMed ID: 3082479
[TBL] [Abstract][Full Text] [Related]
54. [Differential cytologic diagnosis of serous and mucinous ovarian tumors].
Agamova KA; Gladunova ZD; Nikitina NI
Lab Delo; 1986; (2):77-9. PubMed ID: 2421066
[No Abstract] [Full Text] [Related]
55. Detection of early-stage ovarian cancer by FDG-PET-CT in a patient with BRCA2-positive breast cancer.
Milam RA; Milam MR; Iyer RB
J Clin Oncol; 2007 Dec; 25(35):5657-8. PubMed ID: 18065738
[No Abstract] [Full Text] [Related]
56. Huge primary retroperitoneal mucinous cystadenoma of borderline malignancy mimicking an ovarian mass: case report and review.
Bifulco G; Mandato VD; Giampaolino P; Nappi C; De Cecio R; Insabato L; Tarsitano F; Mignogna C
Anticancer Res; 2008; 28(4C):2309-15. PubMed ID: 18751411
[TBL] [Abstract][Full Text] [Related]
57. Allelotype of human ovarian cancer.
Sato T; Saito H; Morita R; Koi S; Lee JH; Nakamura Y
Cancer Res; 1991 Oct; 51(19):5118-22. PubMed ID: 1655245
[TBL] [Abstract][Full Text] [Related]
58. [Chromosome aberrations as morphological criteria of the effectiveness of chemotherapy of ovarian tumors].
Irzhanov SI; Neĭshtadt EL; Aĭnbinder NM
Akush Ginekol (Mosk); 1981 Sep; (9):22-4. PubMed ID: 7332665
[No Abstract] [Full Text] [Related]
59. [Molecular markers in ovarian cancer].
Mazurek A; Pierzyński P; Laudański T
Ginekol Pol; 1998 Feb; 69(2):94-7. PubMed ID: 9591389
[TBL] [Abstract][Full Text] [Related]
60. [CYTOLOGIC EXAMINATION OF ASCITIC FLUID AS A METHOD FOR THE DETECTION OF OVARIAN TUMORS].
KLIMANOVA ZF
Akush Ginekol (Mosk); 1964; 40():55-61. PubMed ID: 14248258
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
